Pacira BioSciences Inc., manufacturers of the pain reliever Exparel, have proposed that an innovative processing method, extending the medication’s shelf life, should warrant an extension of the product’s patent exclusivity period. This argument has been presented to a New Jersey judge currently handling infringement claims brought against eVenus, a generic drug manufacturing company.
Claiming a noteworthy improvement in their product’s stability, Pacira emphasizes this advancement as a reason to lengthen their patent’s monopoly period. Considering the complex world of pharmaceutical patents, any favorable ruling from the judge in this matter could create intrigue among industry leaders, as it presents the opportunity for companies to potentially extend their patents following product enhancements.
The case continues to unfold, with keen interest from both the pharmaceutical and legal industries. Industry pros and legal professionals interested in the intricate case developments involving Pacira BioSciences Inc. and eVenus can follow the details of this ongoing legal battle on Law360.